Intervacc AB (publ) (FRA:2E9)

Market Cap	37.93M +20.6%
Revenue (ttm)	1.86M +70.4%
Net Income	-7.47M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0609
Previous Close	0.0581
Day's Range	0.0609 - 0.0609
52-Week Range	0.0067 - 0.1118
Beta	n/a
RSI	60.34
Earnings Date	Apr 14, 2026

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1983
• Employees: 16
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2E9

Financial Performance

In 2025, Intervacc AB's revenue was 20.09 million, an increase of 70.42% compared to the previous year's 11.79 million. Losses were -80.82 million, 7.02% more than in 2024.

Financial numbers in SEK